Date: 20 January 2011
Source: http://keionline.org/node/1063
Link: http://keionline.org/sites/default/files/CEWGconflictofinterestNGOsignon.pdf
On January 20, 2011, 9 civil society organizations sent a letter to the WHO Executive Board
registering an objection to the selection of Dr. Paul Herrling of Novartis to
the WHO Consultative Expert Working Group on Research and Development:
Financing and Coordination. The groups signing the letter were:
- CIDEPRO
- Déclaration de Berne - Berne
Declaration
- HAI Europe
- HAI Global
- Health GAP (Global Access
Project)
- Knowledge Ecology International
- Médecins Sans Frontières,
Campaign for Access to Essential Medicines
- Oxfam International
- Third World Network
20 January 2011
TO: Dr. Mihaly Kökény,
Chairman, WHO Executive Board
CC: Dr. Paulo Buss, Vice-Chairman, WHO Executive Board
The undersigned organizations oppose the appointment of Novartis executive Dr
Paul Herrling to the new WHO Consultative Expert Working Group (CEWG) on
R&D Financing. In collaboration with Novartis and the
industry trade association IFPMA, Dr Herrling is the author of the Fund for
R&D in Neglected Diseases (FRIND) proposal. Dr. Herrling is also the co-author
of the PDP Plus proposal. The CEWG is expected to evaluate the FRIND and the
PDP Plus proposals. The appointment of Dr. Herrling creates a conflict of
interest. We note that a conflict of interest may exist even if no unethical or
improper act results from it, and also
that both actual and perceived conflicts of interest can undermine the
reputation and work of the CEWG.
Sincerely,
CIDEPRO
Déclaration de Berne -Berne
Declaration
HAI Europe
HAI Global
Health GAP (Global Access Project)
Knowledge Ecology International
Medecins Sans Frontieres, Campaign for Access to Essential Medicines
Oxfam International
Third World Network
|